Karyopharm Therapeutics

KPTI · NASDAQ

$0.3586+$0.0126 (+3.64%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $0.346

KPTI analyst rating

BuyConsensus of 6 analysts over the last 12 months. 83% rate it a buy.

Strong buy0
Buy5
Hold1
Underperform0
Sell0

12-month price target · 6 analysts

Average $7.39 (+1962.2% upside)

Low: $3.03
Now: $0.3586
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

KPTI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Jul 31, 2026	Maintains	Overweight	$16.00 → $7.00	40%
HC Wainwright & Co.	Jul 31, 2026	Downgrade	Buy → Neutral	$13.00 → $3.00	41%
HC Wainwright & Co.	May 6, 2026	Maintains	Buy	$8.00 → $13.00	41%
Piper Sandler	Apr 27, 2026	Maintains	Overweight	$8.00 → $16.00	40%
Piper Sandler	Mar 30, 2026	Maintains	Overweight	$12.00 → $8.00	40%
Baird	Mar 25, 2026	Maintains	Outperform	$21.00 → $15.00	43%
HC Wainwright & Co.	Mar 25, 2026	Maintains	Buy	$15.00 → $8.00	41%
Rodman & Renshaw	Mar 10, 2026	Initiates	Buy	$28.00	38%
HC Wainwright & Co.	Feb 18, 2026	Maintains	Buy	$15.00	41%
Cantor Fitzgerald	Feb 5, 2026	Initiates	Overweight	—	20%

The case for and against

Updated Oct 14, 2026

Bull case

Karyopharm Therapeutics is viewed positively because selinexor has shown unusually strong biomarker-driven efficacy in TP53 wild-type endometrial cancer, where SIENDO subgroup data showed a 65% reduction in progression or death and mPFS of 39.5 months versus 4.9 months on placebo. The upcoming Phase III XPORT-EC-042 readout in mid’26 is a major catalyst, with roughly 220 patients in the mITT analysis and 276 in the ITT population, and a positive result could meaningfully expand XPOVIO’s label and revenue base; U.S. net revenues were $114.9 million in 2025 and are guided at $115-130 million in 2026. In myelofibrosis, SENTRY added further upside by meeting SVR35 at 49.8% versus 28% on ruxolitinib and showing an OS benefit at ~12 months, while cash into 3Q:26 reduces near-term financing risk.

Bear case

Karyopharm Therapeutics is under pressure because the FDA withdrew XPOVIO’s accelerated approval in 3L+ DLBCL after the company could not complete the confirmatory trial amid an evolving treatment landscape, forcing it to stop further development in that indication. The setback removes a revenue stream, while selinexor still faces meaningful execution risk in relapsed/refractory multiple myeloma, myelofibrosis, and endometrial cancer, including a missed Abs-TSS co-primary endpoint in the Phase III SENTRY trial and uncertainty in XPORT-EC-042. Financially, the company carries outstanding debt, will likely need additional capital, and faces long-term dilution risk despite a $457M total projected market value under a DCF approach.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.